PPARD and metabolic dysfunction-associated steatohepatitis: With preclinical models continuing to show NASH improvement with elafibranor treatment [151,152] as well as the suppression of HCC with PPARδ activation [153,154], the future of PPARδ-targeting therapies in the treatment of NAFLD and NAFLD-related HCC is possible.